Live from asco 2025 | ascentage pharma releases promising clinical data on alrizomadlin monotherapy and combinations in solid tumors

Rockville, md. and suzhou, china, june 02, 2025 (globe newswire) -- ascentage pharma (nasdaq: aapg; hkex: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its phase ii study of the mdm2-p53 inhibitor alrizomadlin (apg-115) as a single agent or in combination with pd-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma (acc) or other solid tumors in a poster presentation at the 61st american society of clinical oncology (asco) annual meeting. alrizomadlin is the first mdm2-p53 inhibitor to enter clinical development in china and a key investigational drug candidate in ascentage pharma's apoptosis-targeted pipeline with global first-in-class potential.
AAPG Ratings Summary
AAPG Quant Ranking